Clinical Trials
82 trialsVIRO-25
Genelux Corporation
ROWAN
Boston Scientific Corporation
REZILIENT2
Taiho Oncology, Inc.
DG-03
AstraZeneca
SAVANNAH
AstraZeneca
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Iovance Biotherapeutics, Inc.
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Pfizer
An Adjuvant Study to Evaluate SMS001 (Paclitaxel) in Non-Small Cell Lung Cancer
ToLymph Inc.
CoC
AstraZeneca
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
NATCO Pharma Ltd.
Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies
Revolution Medicines, Inc.
Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)
NiKang Therapeutics, Inc.
RUBY-J
GlaxoSmithKline
Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma
Verrica Pharmaceuticals Inc.
CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Regeneron Pharmaceuticals
CERPASS
Replimune, Inc.
Evaluation Glizigen® and Ocoxin®-Viusid® in High-grade Cervical Intraepithelial Lesions
Catalysis SL
DUNCAN
Philogen S.p.A.
INCAGN01876 in Combination With Immunotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Incyte Corporation
STARRS
Karyopharm Therapeutics Inc
PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)
Amgen
I-PACE
Centessa Pharmaceuticals plc
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
Catalysis SL
A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer
UCB Pharma
Evaluation of Enzastaurin in the Treatment of Persistent or Recurrent Ovarian or Primary Peritoneal Cancer
Eli Lilly and Company
A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC
Eli Lilly and Company
Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
Symphogen A/S
DENALI
Mereo BioPharma
Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.
MultiVir, Inc.
Study Comparing AlloVax™ to Chemotherapy in Recurrent/Metastatic Squamous Cell Carcinoma of the Head & Neck
Mirror Biologics, Inc.
Study of Pralatrexate to Treat Advanced or Metastatic Relapsed Transitional Cell Carcinoma of the Urinary Bladder
Acrotech Biopharma Inc.
A Study in Advanced Solid Tumors
Eli Lilly and Company
Study in Advanced Solid Tumors
Eli Lilly and Company
A Study of Cixutumumab (IMC-A12) in Islet Cell Cancer
Eli Lilly and Company
RAMSETE/CDE16
Novartis
Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung
Pfizer
Study of the Trifunctional Antibody Catumaxomab to Treat Recurrent Symptomatic Malignant Ascites
Neovii Biotech
Safety and Efficacy Clinical Study of SNS-595 for Second-Line Therapy in Patients With Advanced NSCLC
Sunesis Pharmaceuticals
Safety and Efficacy Clinical Study of SNS-595 in Patients With Advanced Small Cell Lung Cancer
Sunesis Pharmaceuticals
Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)
Novartis
Phase II Study of PX-12 in Patients With Advanced Pancreatic Cancer
Seagen Inc.
Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer
Galectin Therapeutics Inc.
Safety and Efficacy Clinical Study of SNS-595 in Patients With Platinum-Resistant Ovarian Cancer
Sunesis Pharmaceuticals
Sequencing of Sipuleucel-T and ADT in Men With Non-metastatic Prostate Cancer
Dendreon
Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer
Novartis
EPO906 in Carcinoid and Other Neuroendocrine Tumors
Novartis
A Phase II Study to Evaluate Efficacy and Safety of Dovitinib (TKI258) in Advanced Scirrhous Gastric Carcinoma Patients
Novartis
EPO906 Therapy in Patients With Prostate Cancer
Novartis
SPRINT
Merck KGaA, Darmstadt, Germany
MACS0460
Novartis